A Phase II Open-Label, Single-arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years With cSSTI or Bacteremia Caused by Gram-positive Cocci

MLA

“A Phase II Open-Label, Single-Arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years With CSSTI or Bacteremia Caused by Gram-Positive Cocci.” Pharma Business Week, 10 Sept. 2018, p. 141. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.553547434&authtype=sso&custid=ns315887.

APA

A Phase II Open-Label, Single-arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years With cSSTI or Bacteremia Caused by Gram-positive Cocci. (2018, September 10). Pharma Business Week, 141.

Chicago

Pharma Business Week. 2018. “A Phase II Open-Label, Single-Arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years With CSSTI or Bacteremia Caused by Gram-Positive Cocci,” September 10. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.553547434&authtype=sso&custid=ns315887.